Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Research

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel

Authors: Mohamed K Hassan, Hidemichi Watari, Yimin Han, Takashi Mitamura, Masayoshi Hosaka, Lei Wang, Shinya Tanaka, Noriaki Sakuragi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Background

Clusterin is a cytoprotective chaperone protein involved in numerous physiological processes, carcinogenesis, tumor growth and tissue remodelling. The purpose of this study was to investigate whether clusterin (CLU), an antiapoptotic molecule, could be a potential predictor molecule for ovarian cancer and whether or not targeting this molecule can improve survival of ovarian cancer patients.

Methods

Clusterin expression was compared between ten primary and their recurrent tumors from same patients immunohistochemically. We analyzed prognostic significance of CLU expression in another 47 ovarian cancer tissue samples by immunohistochemistry. We used small interference RNA to knock down CLU in the chemo-resistant ovarian cancer cell lines. KF-TX and SKOV-3-TX, paclitaxel-resistant ovarian cancer cells, were established from parental KF and SKOV-3 chemo-sensitive cell lines, respectively. Either siRNA or second generation antisense oligodeoxynucleotide against CLU (OGX-011), which is currently evaluated in clinical phase II trials in other cancer s, was used to modulate sensitivity to paclitaxel (TX) in ovarian cancer cells in vitro. Cellular viability assay, FACS analysis and annexin V staining were used to evaluate the comparative effect of CLU knocking down in ovarian cancer cells.

Results

Immunohistochemical analysis of CLU expression in primary ovarian cancer tissue specimens and their recurrent counterparts from same patients demonstrated higher expression of CLU in the recurrent resistant tumors compared with their primary tumors. High expression of CLU by immunohistochemistry among 47 surgical tissue specimens of early-stage (stage I/II) ovarian cancer, who underwent complete cytoreduction as a primary surgery, significantly related to poor survival, while none of other clinicopathological factors analyzed were related to survival in this patient cohort. Secretory CLU (s-CLU; 60 KDa) expression was upregulated in TX-resistant ovarian cancer cells compared to parental cells. Transfection of siRNA or OGX-011 clearly reduced CLU expression. Cell viability assay, FACS analysis and annexin V staining demonstrated that targeting CLU expression by siRNA or OGX-011 sensitized ovarian cancer cells to TX.

Conclusion

We conclude that CLU could be a potential molecular target to predict survival while targeting this s-CLU may improve survival of patients with ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Matsumoto Y, Takano H, Fojo T: Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. 1997, 57: 5086-5092.PubMed
2.
Yap TA, Carden CP, Kaye SB: Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Rev Cancer. 2009, 9: 167-81. 10.1038/nrc2583.CrossRef
3.
Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, et al: Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989, 32: 65-71. 10.1016/0090-8258(89)90852-4.CrossRefPubMed
4.
Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996, 60: 412-7. 10.1006/gyno.1996.0065.CrossRefPubMed
5.
Miller M, Ojima I: Chemistry and Chemical biology of taxan anticancer agents. The Chem Record. 2001, 1: 195-211. 10.1002/tcr.1008.CrossRef
6.
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-9. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed
7.
Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002, 100: 281-7. 10.1016/S0029-7844(02)02040-9.CrossRefPubMed
8.
Reed E, Yu JJ, Davies A, Gannon J, Armentrout S: Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 2003, 9: 5299-305.PubMed
9.
Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES: Silencing expression of the clusterin ⁄/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004, 64: 1834-42. 10.1158/0008-5472.CAN-03-2664.CrossRefPubMed
10.
Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006, 13: 12-9. 10.1038/sj.cdd.4401779.CrossRefPubMed
11.
Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Gleave M, et al: Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology. 2006, 68: 609-14. 10.1016/j.urology.2006.03.017.CrossRefPubMed
12.
Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al: Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997, 3: 1707-1711.PubMed
13.
Parczyk K, Pilarsky C, Rachel U, Koch-Brandt C: Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol. 1994, 120: 186-188. 10.1007/BF01202200.CrossRefPubMed
14.
Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000, 157: 393-9. 10.1016/S0002-9440(10)64552-X.PubMedCentralCrossRefPubMed
15.
Xie D, Lau SH, Sham JS, Wu QL, Fang Y, Liang LZ, et al: Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer. 2005, 103: 277-283. 10.1002/cncr.20765.CrossRefPubMed
16.
Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene. 2004, 23: 2298-2304. 10.1038/sj.onc.1207404.CrossRefPubMed
17.
July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al: Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004, 3: 223-32. 10.4161/cbt.3.2.775.PubMed
18.
Mourra N, Couvelard A, Tiret E, Olschwang S, Flejou JF: Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours. Histopathology. 2007, 50: 331-337. 10.1111/j.1365-2559.2007.02608.x.CrossRefPubMed
19.
Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N: Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol. 2008, 108: 527-32. 10.1016/j.ygyno.2007.11.026.CrossRefPubMed
20.
Danik M, Chabot JG, Mercier C, Benabid AL, Chauvin C, Quirion R, et al: Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci. 1991, 88: 8577-81. 10.1073/pnas.88.19.8577.PubMedCentralCrossRefPubMed
21.
Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, et al: Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000, 96: 398-404.PubMed
22.
Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al: A phase I pharmacokinetic and pharmacodynamic study of ogx-011, a 20-methoxyethyl antisense oligonucleotide to clusterin in patients with localized prostate cancer. J Natl Cancer Inst. 2005, 97: 1287-96. 10.1093/jnci/dji252.CrossRefPubMed
23.
July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002, 50: 179-88. 10.1002/pros.10047.CrossRefPubMed
24.
Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME: Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy) ethyl chemistry. J Pharm Exp Ther. 2001, 298: 934-940.
25.
Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF: Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharm Exp Ther. 2000, 292: 468-79.
26.
Yang GF, Li XM, Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gyn Can. 2009, 19: 1342-1346. 10.1111/IGC.0b013e3181a83ed9.CrossRef
27.
Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y, et al: Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer. 2009, 125: 791-806. 10.1002/ijc.24316.CrossRefPubMed
28.
Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, et al: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008, 123: 2130-7. 10.1002/ijc.23758.CrossRefPubMed
29.
Hassan MK: An association between clusterin over-expression and taxol-resistance in ovarian cancer. Hokkaido Igaku Zasshi. 2008, 8: 335-346.
30.
Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, Boothman DA: Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signalling regulates clusterin expression, a pro-survival factor. J Biol Chem. 2005, 14: 14212-14221.CrossRef
31.
Miyake H, Hara S, Arakawa S, Kamidono S, Hara I: Overexpression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol. 2002, 167: 703-6. 10.1016/S0022-5347(01)69130-4.CrossRefPubMed
32.
Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S: Intracellular Clusterin Induces G2-M Phase Arrest and Cell Death in PC-3 Prostate Cancer Cells. Cancer Research. 2004, 64: 6174-6182. 10.1158/0008-5472.CAN-04-0920.CrossRefPubMed
33.
Kruger S, Ola V, Fisher D, Feller AC, Friedrich M: Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma. 2007, 54: 46-50.PubMed
34.
Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK: Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia. 2008, 10: 964-72.PubMedCentralCrossRefPubMed
35.
Lourda M, Trougakos P, Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein. J Int J Cancer. 2006, 120: 611-22.CrossRef
36.
Djeu JY, Wei S: Clusterin and chemoresistance. Adv Can Res. 2009, 105: 77-92.CrossRef
37.
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009, 27: 1419-25. 10.1200/JCO.2008.19.1684.PubMedCentralCrossRefPubMed
38.
Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY: Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Mol Can Ther. 2010, 9: 1831-41. 10.1158/1535-7163.MCT-09-0880.CrossRef
39.
Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR: Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem. 1999, 274: 6875-81. 10.1074/jbc.274.11.6875.CrossRefPubMed
40.
Watari H, Kanuma T, Ohta Y, Hassan MK, Mitamura T, Hosaka M, et al: Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res. 2010, 16: 345-52. 10.1007/s12253-009-9235-0.CrossRefPubMed
41.
Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, et al: Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005, 124: 1300-7. 10.1111/j.0022-202X.2005.23720.x.CrossRefPubMed
42.
Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB, Johnson DH, et al: Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1845-51. 10.1158/1055-9965.EPI-07-0146.CrossRefPubMed
43.
Wu AJ, Park II, Zhaung L, Lee C: Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells. Prostate. 2002, 53: 277-85. 10.1002/pros.10158.CrossRefPubMed
44.
Miyake H, Hara I, Gleave ME: Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer : Vancouver experience from discovery to clinic. Int J Urol. 2005, 12: 785-94. 10.1111/j.1442-2042.2005.01173.x.CrossRefPubMed
45.
Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, et al: Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. B J U Int. 2008, 102: 389-97. 10.1111/j.1464-410X.2008.07618.x.CrossRef
46.
Gleave M, Miyake H: Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemosensitivity in prostate cancer. World J Urol. 2005, 23: 38-46. 10.1007/s00345-004-0474-0.CrossRefPubMed
47.
Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM: Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006, 17: 860-5. 10.1093/annonc/mdl010.CrossRefPubMed
48.
Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, et al: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer. 2005, 92: 532-8.PubMedCentralPubMed
49.
Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA: Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Onco. 2010, 28: 4247-54. 10.1200/JCO.2009.26.8771.CrossRef
Metadata
Title
Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
Authors
Mohamed K Hassan
Hidemichi Watari
Yimin Han
Takashi Mitamura
Masayoshi Hosaka
Lei Wang
Shinya Tanaka
Noriaki Sakuragi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-113

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Research

CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway

Research

Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro

Research

Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis

Research

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

Research

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Review

Platinum resistance in breast and ovarian cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits